G

Genfit SA
PAR:GNFT

Watchlist Manager
Genfit SA
PAR:GNFT
Watchlist
Price: 5.2 EUR 5.05% Market Closed
Market Cap: 260m EUR

Operating Margin
Genfit SA

-61.4%
Current
-37%
Average
-3.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-61.4%
=
Operating Profit
-27.9m
/
Revenue
45.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
FR
Genfit SA
PAR:GNFT
260m EUR
-61%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
395.9B USD
33%
US
Amgen Inc
NASDAQ:AMGN
170.8B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
153B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.3B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.6B USD
28%
AU
CSL Ltd
ASX:CSL
88.7B AUD
26%
NL
argenx SE
XBRU:ARGX
46.3B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
54.4B USD
8%
No Stocks Found

Genfit SA
Glance View

Market Cap
260m EUR
Industry
Biotechnology

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

GNFT Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-61.4%
=
Operating Profit
-27.9m
/
Revenue
45.4m
What is the Operating Margin of Genfit SA?

Based on Genfit SA's most recent financial statements, the company has Operating Margin of -61.4%.

Back to Top